[go: up one dir, main page]

MX2021006121A - Profarmaco de gemcitabina oralmente activo. - Google Patents

Profarmaco de gemcitabina oralmente activo.

Info

Publication number
MX2021006121A
MX2021006121A MX2021006121A MX2021006121A MX2021006121A MX 2021006121 A MX2021006121 A MX 2021006121A MX 2021006121 A MX2021006121 A MX 2021006121A MX 2021006121 A MX2021006121 A MX 2021006121A MX 2021006121 A MX2021006121 A MX 2021006121A
Authority
MX
Mexico
Prior art keywords
gemcitabine
orally active
sub
active prodrug
prodrug
Prior art date
Application number
MX2021006121A
Other languages
English (en)
Inventor
Xiang Li
Bing Ying Li
Starr Sing Chung Cheng
Andrew Wang
Original Assignee
Tnt Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tnt Medical Corp filed Critical Tnt Medical Corp
Publication of MX2021006121A publication Critical patent/MX2021006121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La exposición incluye compuestos de la Fórmula (I): (Ver formula) en donde R1, R2 y R3 se definen en la presente. También se describe un método para tratar una enfermedad neoplásica con estos compuestos.
MX2021006121A 2018-11-25 2019-11-22 Profarmaco de gemcitabina oralmente activo. MX2021006121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862771100P 2018-11-25 2018-11-25
PCT/US2019/062747 WO2020107013A1 (en) 2018-11-25 2019-11-22 Orally active prodrug of gemcitabine

Publications (1)

Publication Number Publication Date
MX2021006121A true MX2021006121A (es) 2021-10-13

Family

ID=70774630

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006121A MX2021006121A (es) 2018-11-25 2019-11-22 Profarmaco de gemcitabina oralmente activo.

Country Status (12)

Country Link
US (1) US20220033430A1 (es)
EP (1) EP3883947A4 (es)
JP (1) JP2022510169A (es)
KR (1) KR20210096160A (es)
CN (1) CN113939525A (es)
AU (1) AU2019384826A1 (es)
BR (1) BR112021009988A2 (es)
CA (1) CA3120941A1 (es)
IL (1) IL283375A (es)
MX (1) MX2021006121A (es)
SG (1) SG11202105512PA (es)
WO (1) WO2020107013A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
GB202203421D0 (en) 2022-03-11 2022-04-27 Laevoroc Chemotherapy Ag Orally active prodrug of gemcitabine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633367A (en) * 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
DE19924818A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
AU2007255856B2 (en) * 2006-06-02 2012-08-16 Meiji Seika Pharma Co., Ltd. Novel aminoglycoside antibiotic
EP2408306A4 (en) * 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
US20120070411A1 (en) * 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
CN105288648B (zh) * 2015-10-14 2018-11-06 东南大学 一种亲水性药物的磷脂化合物、其药物组合物及应用

Also Published As

Publication number Publication date
JP2022510169A (ja) 2022-01-26
SG11202105512PA (en) 2021-06-29
CA3120941A1 (en) 2020-05-28
US20220033430A1 (en) 2022-02-03
BR112021009988A2 (pt) 2021-08-17
EP3883947A4 (en) 2022-08-24
KR20210096160A (ko) 2021-08-04
IL283375A (en) 2021-07-29
AU2019384826A1 (en) 2021-07-15
CN113939525A (zh) 2022-01-14
EP3883947A1 (en) 2021-09-29
WO2020107013A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2025002170A (es) Inhibidores de kras g12c
MX2025008593A (es) Inhibidores de cdk
CL2022001731A1 (es) Inhibidores de egfr.
PH12021551317A1 (en) Modulators of trex1
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
CL2024000067A1 (es) Compuestos antivirales
WO2017132474A8 (en) Bcl-2 inhibitors
MX2025011447A (es) Inhibidores de kras
CR20220251A (es) Nuevos derivados de metilquinazolinona
PH12021552482A1 (en) Compounds targeting prmt5
MX2020008627A (es) Inhibidores de btk y mutantes de los mismos.
MX2024000230A (es) Inhibidores de cdk2.
WO2021079196A3 (en) Mettl3 modulators
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2021007258A (es) Composiciones de esparsentan amorfas.
MX2022007626A (es) Combinaciones.
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
MX2021006121A (es) Profarmaco de gemcitabina oralmente activo.
WO2018005444A3 (en) Methods for treating cancer
PH12023553004A1 (en) Modulators of trex1
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
CR20230542A (es) Moduladores de trex1
WO2017210371A3 (en) Compounds as inhibitors of sodium channels